Compare HBB & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HBB | CNTX |
|---|---|---|
| Founded | 1904 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.9M | 283.9M |
| IPO Year | 2017 | 2021 |
| Metric | HBB | CNTX |
|---|---|---|
| Price | $19.57 | $2.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.60 |
| AVG Volume (30 Days) | 15.5K | ★ 719.6K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.38% | N/A |
| EPS Growth | N/A | ★ 17.39 |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $606,852,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $75.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.72 | $0.49 |
| 52 Week High | $21.84 | $3.62 |
| Indicator | HBB | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.60 | 59.42 |
| Support Level | $17.95 | $2.10 |
| Resistance Level | $20.44 | $2.90 |
| Average True Range (ATR) | 1.28 | 0.14 |
| MACD | -0.06 | 0.03 |
| Stochastic Oscillator | 60.30 | 100.00 |
Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels. It has two operating segments Home and Commercial Products segment includes consumer product revenue consisting of sales of small electric household and specialty housewares appliances whereas the health segment includes lease revenue associated with leases of connected devices to specialty pharmacy networks and pharmaceutical companies, as well as licensing revenue which grant customers the right to use software for healthcare management.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.